Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 15/20 | 0.43 |
| ▸ | CCKAR | P32238 | 9/20 | 0.43 |
| ▸ | FPR1 | P21462 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NOTCH1 | P46531 | 1/20 | 0.40 |
| ▸ | RBPJ | Q06330 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20098072 | 1.00 | CCKBR (0.43) | CCKBRCCKARFPR1FPR2MEN1 | |
| SCHEMBL20098226 | 0.88 | KDM4E (0.48) | CCKBRCCKARFPR1FPR2ALDH1A1 | |
| SCHEMBL21755183 | 0.88 | KDM4E (0.48) | CCKBRCCKARFPR1FPR2ALDH1A1 | |
| SCHEMBL21755254 | 0.87 | CCKBR (0.43) | CCKBRCCKARMEN1ALDH1A1KMT2A | |
| SCHEMBL20098061 | 0.87 | CCKBR (0.43) | CCKBRCCKARMEN1ALDH1A1KMT2A | |
| SCHEMBL20866958 | 0.86 | CCKBR (0.41) | CCKBRCCKARFPR1FPR2MEN1 | |
| SCHEMBL20098380 | 0.86 | CCKBR (0.41) | CCKBRCCKARFPR1FPR2MEN1 | |
| SCHEMBL20098394 | 0.86 | CCKBR (0.48) | CCKBRCCKARFPR1FPR2MEN1 | |
| SCHEMBL21755250 | 0.86 | CCKBR (0.48) | CCKBRCCKARFPR1FPR2MEN1 | |
| SCHEMBL20098144 | 0.86 | CCKBR (0.48) | CCKBRCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | CCKBR 509/4885CCKAR 989/4885FPR1 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.